Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Finished Goods (2024 - 2025)

Day One Biopharmaceuticals (DAWN) has disclosed Finished Goods for 2 consecutive years, with $2.0 million as the latest value for Q4 2025.

  • Quarterly Finished Goods rose 128.29% to $2.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.0 million through Dec 2025, up 128.29% year-over-year, with the annual reading at $2.0 million for FY2025, 128.29% up from the prior year.
  • Finished Goods for Q4 2025 was $2.0 million at Day One Biopharmaceuticals, up from $1.1 million in the prior quarter.
  • The five-year high for Finished Goods was $2.0 million in Q4 2025, with the low at $873000.0 in Q4 2024.